Gelteq Limited

Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. A "white label" gel-based delivery solution means Gelteq produces a product that other companies rebrand as their own. The company's principal products are edible gels and their application in gel-based dosage forms. Gelteq's current product suite includes multiple products across five core verticals: pets, sports, pharmaceutical (pharma), over-the-counter (OTC), and nutraceutical. All these products utilize the company's patent-pending multiple-ingredient dosage forms. Gelteq currently focuses on out-licensing its technology to companies for developing and creating new products they can manufacture and sell within their established markets, while Gelteq continues to manufacture its existing products under license ("white label"). In October 2023, Gelteq received an order for 200,000 units in its nutraceutical vertical, along with a non-refundable deposit of AUD$40,000 (USD$26,000). These orders were shipped in the fiscal year ending June 30, 2025. The company has implemented more rigorous qualification procedures for future customers to ensure financial capability for timely order funding through manufacturing. Products in the pets, nutraceutical, and sports verticals are designed with food-grade classifications, requiring no regulatory approvals. The gel platform is designed to enhance drug tolerability and stability while maintaining efficacy. Products in the pharma vertical will require regulatory approval. For the fiscal year ended June 30, 2025, Gelteq prioritized research and development, its initial public offering, and adjustments to management and operations to achieve sales targets.